Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

13,481 total articles

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

Corbus Pharmaceuticals has appointed Brent Pfeiffenberger, a seasoned pharma executive with extensive leadership roles at Bristol Myers Squibb and Century Therapeutics, to its Board of Directors. His expertise is expected to support Corbus’ ongoing development of its oncology treatment CRB-701 and obesity treatment CRB-913. The company anticipates …

SoundThinking Appoints David Jochim as Senior Vice President of TechnoLogic and Professional Services

SoundThinking Appoints David Jochim as Senior Vice President of TechnoLogic and Professional Services

SoundThinking, a NASDAQ-listed public safety tech company, announced David Jochim as their new Senior Vice President of TechnoLogic and Professional Services. Jochim is expected to strengthen operational discipline and grow the customer base for the TechnoLogic division, which supports the NYPD's Enterprise Case Management System and the CaseBuilde…

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on novel cancer therapies, announced that its President and CEO, Angelos Stergiou, will participate in several upcoming investor conferences in May 2026, where corporate presentations and fireside chats will be conducted. The company highlighted its lead drug …

Synergy CHC Corp. Reports First Quarter 2026 Financial Results

Synergy CHC Corp. Reports First Quarter 2026 Financial Results

Synergy CHC Corp., a US consumer health and wellness company, reported first quarter 2026 financial results showing a revenue decline to $5.49 million from $8.17 million year-over-year, primarily due to non-recurrence of license revenue and out-of-stock issues. However, its functional beverage segment showed strong momentum with revenues exceeding …

La Rosa Holdings Provides Update on Proposed Consensus Core Transaction Anticipates Definitive Agreements Within 45 to 60 Days, Subject to Customary Conditions

La Rosa Holdings Provides Update on Proposed Consensus Core Transaction Anticipates Definitive Agreements Within 45 to 60 Days, Subject to Customary Conditions

La Rosa Holdings Corp. announced ongoing progress in its proposed transaction with Consensus Core Technologies, with expected definitive agreements anticipated within 45 to 60 days, subject to customary conditions. The transaction aims to create strategic opportunities for both companies. La Rosa Holdings is a real estate and PropTech company opera…

Prenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M

Prenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M

Prenetics Global Limited announced preliminary Q1 2026 results showcasing a substantial revenue increase to $36 million, driven primarily by its IM8 brand which reported $33.8 million, reflecting 23.1% growth over Q4 2025 and nearly sixfold year-over-year growth. The company raised its full-year IM8 revenue guidance to $190 million to $210 million …

BranchOut Food Shareholder Update: Record Production and Major Customer Deliveries Position Company for Record Q2

BranchOut Food Shareholder Update: Record Production and Major Customer Deliveries Position Company for Record Q2

BranchOut Food Inc. achieved record production in March and Q2 2026, driven by a major order to the nation's second largest warehouse club retailer and expansion with the largest warehouse club retailer. The company anticipates Q2 to be a record revenue quarter fueled by these deliveries and a potential high-margin tolling partnership nearing compl…

Intuitive Machines Reports First Quarter 2026 Financial Results; Posts Record Quarterly Revenue, Gross Margin, and Positive Adjusted EBITDA along with Record Quarter-end Backlog of $1.1 Billion

Intuitive Machines Reports First Quarter 2026 Financial Results; Posts Record Quarterly Revenue, Gross Margin, and Positive Adjusted EBITDA along with Record Quarter-end Backlog of $1.1 Billion

Intuitive Machines reported strong first quarter 2026 financial results, highlighted by record quarterly revenue of $186.7 million, positive adjusted EBITDA, and backlog growth driven by the $800 million acquisition of Lanteris Space Systems. The acquisitions and new contracts with NASA, U.S. Space Force, and Space Development Agency position the c…

Agomab to Participate in Upcoming Conferences

Agomab to Participate in Upcoming Conferences

Agomab Therapeutics, a clinical-stage biopharmaceutical company specializing in fibro-inflammatory disease treatments, will participate in several prominent healthcare and investor conferences throughout 2026. The company will present preclinical data on its inhaled TGFβR1/ALK5 inhibitor aimed at treating idiopathic pulmonary fibrosis and engage in…

EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer

EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer

EDAP TMS S.A. announced a letter of intent with Telix Pharmaceuticals to collaborate on clinical research and physician education combining EDAP's Focal One Robotic HIFU therapy and Telix's PSMA PET imaging products for enhanced prostate cancer treatment. This partnership aims to integrate advanced imaging and robotic therapy to optimize treatment …

Electra Reports Q1 2026 Progress as Refinery Construction Accelerates

Electra Reports Q1 2026 Progress as Refinery Construction Accelerates

Electra Battery Materials Corporation reported significant progress in Q1 2026 on its cobalt sulfate refinery construction project in Ontario, Canada. The company approved a $73 million construction budget, awarded key contracts, secured a strategic supply agreement with LG Energy Solution, and obtained $20 million in government funding to support …

Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics announced receipt of a second philanthropic donation that allows the continuation of its expanded access program (EAP) providing Zervimesine (CT1812) treatment to patients with Dementia with Lewy Bodies (DLB). The EAP, launched in 2025 and currently serving 32 participants, is now extended to two years of treatment. Positive …

Milestone Scientific Reports Financial Results for First Quarter 2026

Milestone Scientific Reports Financial Results for First Quarter 2026

Milestone Scientific Inc. announced its Q1 2026 financial results showing a 30% reduction in operating expenses, significantly narrowed operating loss, and stable revenue despite Middle East shipping challenges. Medical segment revenues more than doubled year-over-year. The company completed a $2.15 million financing in April 2026 to support growth…

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

MiNK Therapeutics has initiated a randomized Phase 2 clinical trial evaluating their off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797, in patients with severe acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The study, conducted in partnership with First Lviv Territorial Medical Union and sup…

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

HCW Biologics announced that its immunotherapeutic candidate HCW11-040, a pembrolizumab-based fusion protein, successfully prevented bronchopulmonary dysplasia (BPD) in an animal model during IND-enabling studies. The company plans to complete these studies by late 2027 and file an IND application promptly to treat infants at high risk of BPD, a ra…

Genie Energy Announces First Quarter 2026 Results

Genie Energy Announces First Quarter 2026 Results

Genie Energy Ltd. announced its Q1 2026 financial results showing record revenue growth to $142.3 million but significant declines in gross profit, operating income, and adjusted EBITDA due to margin compression and higher customer acquisition costs. The company lowered its full-year 2026 adjusted EBITDA guidance citing ongoing margin pressures and…

Fiserv Forms Strategic Collaboration with OpenAI to Bring AI to How Fiserv Serves Financial Institutions

Fiserv Forms Strategic Collaboration with OpenAI to Bring AI to How Fiserv Serves Financial Institutions

Fiserv, a leading financial technology company, has announced a strategic collaboration with OpenAI to incorporate frontier AI technologies into its platforms serving financial institutions. The partnership focuses on building strategic AI agents, accelerating banking modernization efforts, developing banking-specific AI capabilities, and enhancing…

Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

Celcuity Inc., a clinical-stage biotech company, announced an expansion of its Phase 3 VIKTORIA-2 study evaluating gedatolisib for HR+/HER2- advanced breast cancer to now include endocrine-sensitive patients, alongside endocrine-resistant ones. The company also submitted a patent application for a subcutaneous version of gedatolisib to improve long…